Journal article
18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease
MT Fodero-Tavoletti, N Okamura, S Furumoto, RS Mulligan, AR Connor, CA McLean, D Cao, A Rigopoulos, GA Cartwright, G O'Keefe, S Gong, PA Adlard, KJ Barnham, CC Rowe, CL Masters, Y Kudo, R Cappai, K Yanai, VL Villemagne
Brain | OXFORD UNIV PRESS | Published : 2011
DOI: 10.1093/brain/awr038
Abstract
While considerable effort has focused on developing positron emission tomography β-amyloid imaging radiotracers for the early diagnosis of Alzheimer's disease, no radiotracer is available for the non-invasive quantification of tau. In this study, we detail the characterization of 18F-THK523 as a novel tau imaging radiotracer. In vitro binding studies demonstrated that 18F-THK523 binds with higher affinity to a greater number of binding sites on recombinant tau (K18Δ280K) compared with β-amyloid1-42 fibrils. Autoradiographic and histofluorescence analysis of human hippocampal serial sections with Alzheimer's disease exhibited positive THK523 binding that co-localized with immunoreactive tau p..
View full abstractGrants
Awarded by Association of American Railroads
Funding Acknowledgements
National Health and Medical Research Council of Australia (in part); Neurosciences Victoria and the Ministry of Health, Labour and Welfare, Japan (in part); Industrial Technology Research Grant Program in 2009 from New Energy and Industrial Technology Development Organization (NEDO) of Japan(in part); AAR Viertel Fellowship (to M.T.F.-T.); NHMRC Senior Research Fellowship (to R. C. and K.J.B.). Perpetual Trustees H & L Hecht Trust.